SYN-NAT
LIVE

Serial Number

88912528

Owner

Medoncare Pharmaceutical Co., Ltd.

Attorney

Timothy T. Wang

First Use Date

Sep 22, 2023

Filing Date

May 12, 2020

Add to watchlist:

No watchlists yet
View on USPTO

SYN-NAT Trademark

Serial Number: 88912528 • Registration: 7724324

SYN-NAT is a trademark filed by Medoncare Pharmaceutical Co., Ltd. on May 12, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Medoncare Pharmaceutical Co., Ltd. (7 trademarks)

Building 5, 229 Guyuan Road, Yuelu Dist.
Changsha, Hunan Prov. 410205 , CN

Entity Type: 99

Trademark Details

Filing Date

May 12, 2020

Registration Date

March 11, 2025

First Use Anywhere

September 22, 2023

First Use in Commerce

April 12, 2024

Published for Opposition

April 2, 2024

Goods & Services

Tonics of medicines, namely, medicinal tea; Medicines for human purposes in the form of effervescent tablets, chewable tablet and chewing gum for use in preventing prostatitis, benign prostatic hyperplasia, urinary tract infection, gynecological inflammation, gastrointestinal disease; Medicines for human purposes in the form of effervescent tablets, chewable tablet and chewing gum for use in blood sugar regulation, liver protection, and as antioxidants, anti-hyperlipidemia, anti-aging, antineoplastic and antiviral agents for medical use; Medicines for human purposes, namely, medicines for the treatment of gastrointestinal disease, skin disease, cardiovascular disease, gout, asthma, nasitis, prostatic cancer, leukemia, melanoma, brain glioma, colon cancer, cervical cancer, thyroid cancer, kidney cancer, stomach cancer and lung cancer, hepatitis B, hepatitis C, AIDS and influenza, prostatitis, benign prostatic hyperplasia and gynecological inflammation, diabetes, sleep disorder and rheumatoid arthritis; Medicinal drinks; Capsules sold empty for pharmaceuticals; Pharmaceutical preparations for the treatment of gastrointestinal disease, skin disease, cardiovascular disease, gout, asthma, nasitis, prostatic cancer, leukemia, melanoma, brain glioma, colon cancer, cervical cancer, thyroid cancer, kidney cancer, stomach cancer and lung cancer, hepatitis B, hepatitis C, AIDS and influenza, prostatitis, benign prostatic hyperplasia and gynecological inflammation, diabetes, sleep disorder and rheumatoid arthritis; Chemico-pharmaceutical preparations for tumor-suppression and antiviral treatment; Troches, namely, tablets for use in tumor-suppression, as antivirals and for the treatment of chronic gastrointestinal disease; Tinctura in the nature of medicinal herb extracts; Herbs for medicinal purposes; Nutritional supplements; dietetic foods adapted for medical use, namely, dietetic drinks, dietetic crackers, dietetic sugar for medical use, dietetic sugar substitutes for medical use; Dietary and nutritional supplements; Dietary food supplements; Dietary supplemental drinks; Dietary supplements; Dietetic beverages adapted for medical use; Dietetic foods adapted for medical purposes; Dietetic foods and beverages adapted for medical use; Nutraceuticals for use as a dietary supplement; Nutritional supplements in the form of capsules, tablets, caplets, powder, syrups, gummies and gels; Sanitizing preparations for commercial use

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Mar 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Mar 11, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Feb 15, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Feb 15, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Feb 14, 2025 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 14, 2025 AITU
USE AMENDMENT FILED
Dec 3, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Dec 3, 2024 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 4, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 2, 2024 NPUB
PUBLISHED FOR OPPOSITION
Apr 2, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 13, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 29, 2024 CNSA
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 29, 2023 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 1, 2023 RCSC
ASSIGNED TO EXAMINER
Jan 17, 2023 DOCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sep 1, 2022 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 1, 2022 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 28, 2021 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 17, 2021 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 17, 2021 GNSL
SUSPENSION LETTER WRITTEN
Feb 17, 2021 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 16, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 16, 2021 CRFA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 26, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 26, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 26, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 16, 2020 GNRN
NON-FINAL ACTION E-MAILED
Aug 16, 2020 GNRT
NON-FINAL ACTION WRITTEN
Aug 16, 2020 CNRT
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Aug 15, 2020 GNS3
LETTER OF SUSPENSION E-MAILED
Aug 15, 2020 GNSL
SUSPENSION LETTER WRITTEN
Aug 15, 2020 CNSL
ASSIGNED TO EXAMINER
Aug 8, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 26, 2020 NWOS
NEW APPLICATION ENTERED
May 15, 2020 NWAP